<DOC>
	<DOCNO>NCT00103987</DOCNO>
	<brief_summary>This study examine brain noradrenaline function panic disorder . Noradrenaline brain chemical involve regulation emotion , anxiety , sleep , stress hormone cortisol , body function disturb panic disorder . Healthy normal volunteer patient panic disorder 18 60 year age may eligible study . Candidates screen psychiatric medical history , physical examination , blood urine test , electrocardiogram . Participants undergo follow test procedure : - Blood draw obtain DNA genetic study panic disorder - particularly gene help control noradrenaline activity - grow cell line freeze use future research disorder . - Magnetic resonance imaging : MRI use magnetic field radio wave produce image body tissue organ . For procedure , subject lie table move scanner ( narrow cylinder ) , wear earplugs muffle loud knock thump sound occur scan process . The procedure last 60 minute , patient ask lie still 10 15 minute time . - Yohimbine injection PET scanning : Catheters ( plastic tube ) place two vein , one administer yohimbine , drug increase noradrenaline activity body 60 minute , one draw blood sample . Yohimbine often cause temporary trembling , goosebump , clammy palm , may cause emotion elation , anxiety , panic attack , depression . During yohimbine administration , subject undergo positron emission tomography ( PET ) scan . PET use small amount radioactive chemical call [ fluoro-18 ] -fluorodeoxyglucose `` label '' active area brain , show pattern glucose ( sugar ) metabolism . For procedure , subject lie scanner bed , special mask fit head attach bed help keep head still . A brief `` transmission '' scan do radioactive tracer inject order calibrate scanner . After tracer inject catheter , picture take hour , subject lie still scanner bed . - Saline injection PET scanning : The procedure describe , except saline solution administer placebo instead yohimbine .</brief_summary>
	<brief_title>Neurobiological Mechanisms Panic Disorder</brief_title>
	<detailed_description>A considerable body preclinical clinical evidence suggest dysregulated activity noradrenergic system brain involve development mood disturbance , anxiety , fear . Neuroanatomical neurophysiological study noradrenergic system provide basis relate increase activity system behavioral expression fear anxiety somatic symptom cardiovascular change accompany severe anxiety state . Previously , extensive research do role noradrenergic mechanism panic disorder ( PD ) , suggest least subgroup PD patient abnormality noradrenergic mechanism may exist . Studies patient PD use alpha2-adrenoreceptor ( AR ) antagonist yohimbine show subgroup PD patient exhibit abnormality regulation noradrenergic function . Yohimbine , activate noradrenergic neuron , show produce great increase anxiety , somatic symptom , blood pressure plasma level noradrenergic metabolite MHPG patient PD relative healthy control . The effect yohimbine brain region hypothesize involved pathogenesis PD determine PD patient use modern neuroimaging technique . The anxiogenic effect yohimbine occur PD patient , although neurobiological basis differential response yohimbine identify . This research project propose address two unresolved question . The effect yohimbine regional cerebral glucose metabolism determine PD patient healthy control . In addition , preliminary data obtain whether behavioral cerebral metabolic response yohimbine relate functional polymorphism COMT gene affect catecholamine metabolism . It predict yohimbine produce decrease cerebral metabolism prefrontal cortex , orbitofrontal cortex , anterior cingulate . Healthy control exhibit inverse direction change brain region . These finding would similar previously observe PTSD patient may reflect altered dose-response effect yohimbine PD PTSD relative control since preclinical pharmacological study stress show high level norepinephrine release brain decrease brain metabolism whereas low level increase brain metabolism . In term polymorphisms COMT catecholamine systems-related gene polymorphism , predict low-activity COMT ( meet allele ) allele associate great behavioral cerebral metabolic response yohimbine .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<criteria>INCLUSION CRITERIA : Up 120 drugfree subject ( age 1860 ) select additionally meet criterion one 3 subgroup : I. PD , current ( n=30 ) , define DSMIV criterion PD , still symptomatic define least 1 panic attack/week CGI score least 4 . In case comorbid depression ensure PD primary diagnosis . This mean PD precede onset MDD . These patient drugfree least 2 week prior enrol study . II . PD , remit ( n=30 ) , define DSMIV criterion PD , asymptomatic longer meet criterion PD drugfree past 6 month . III . Healthy Control Sample . Sixty subject ( age 1860 ) meet criterion major psychiatric disorder ( axis I diagnosis accord DSMIV ) . A control subject match PD subject age , gender , menopausal estrogen replacement status , handedness . The control subject know firstdegree relative axis I disorder . EXCLUSION CRITERIA : Symptomatic PD patient must take antidepressant medication likely alter monoamine neurochemistry cerebrovascular cardiovascular function least 2 week prior challenge study . Remitted PD patient drugfree least 6 month prior enrollment . Subjects also exclude : 1. evidence axis I psychiatric disorder ( DSMIV criterion ) panic disorder with/without agoraphobia with/without comorbid depression , 2. medical neurological illness likely affect physiology anatomy , i.e . hypertension , cardiovascular disorder , seizure , 3. history drug ( include BZDs ) alcohol abuse within 1 year lifetime history alcohol drug dependence ( DSM IV criterion ) , 4. current pregnancy ( documented pregnancy test screening day challenge study ) , 5. current breast feeding , 6. smoker , 7. presence axis II personality disorder , 8. current treatment fluoxetine , 9. history adverse reaction associate administration yohimbine . Subjects beyond age 60 exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 12, 2010</verification_date>
	<keyword>Panic Disorder</keyword>
	<keyword>Norepinephrine</keyword>
	<keyword>Yohimbine</keyword>
	<keyword>Genes</keyword>
	<keyword>Pathophysiology</keyword>
	<keyword>Noradrenergic Mechanisms</keyword>
	<keyword>PET Imaging</keyword>
	<keyword>PD</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>